KR102335607B1 - 질염의 치료 - Google Patents

질염의 치료 Download PDF

Info

Publication number
KR102335607B1
KR102335607B1 KR1020160151167A KR20160151167A KR102335607B1 KR 102335607 B1 KR102335607 B1 KR 102335607B1 KR 1020160151167 A KR1020160151167 A KR 1020160151167A KR 20160151167 A KR20160151167 A KR 20160151167A KR 102335607 B1 KR102335607 B1 KR 102335607B1
Authority
KR
South Korea
Prior art keywords
vaginal
cultures
zeolite
growth
clinoptilolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020160151167A
Other languages
English (en)
Korean (ko)
Other versions
KR20170055932A (ko
Inventor
가스톤 글록
Original Assignee
글록 헬스, 사이언스 앤드 리서치 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글록 헬스, 사이언스 앤드 리서치 게엠베하 filed Critical 글록 헬스, 사이언스 앤드 리서치 게엠베하
Publication of KR20170055932A publication Critical patent/KR20170055932A/ko
Application granted granted Critical
Publication of KR102335607B1 publication Critical patent/KR102335607B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020160151167A 2015-11-12 2016-11-14 질염의 치료 Expired - Fee Related KR102335607B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194288.5 2015-11-12
EP15194288.5A EP3167890A1 (de) 2015-11-12 2015-11-12 Behandlung von vaginitis

Publications (2)

Publication Number Publication Date
KR20170055932A KR20170055932A (ko) 2017-05-22
KR102335607B1 true KR102335607B1 (ko) 2021-12-06

Family

ID=54542054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160151167A Expired - Fee Related KR102335607B1 (ko) 2015-11-12 2016-11-14 질염의 치료

Country Status (9)

Country Link
US (1) US20170136060A1 (https=)
EP (2) EP3167890A1 (https=)
JP (1) JP6792420B2 (https=)
KR (1) KR102335607B1 (https=)
CN (1) CN106974932B (https=)
AU (1) AU2016247097B2 (https=)
CA (1) CA2947570C (https=)
ES (1) ES2719223T3 (https=)
TR (1) TR201904382T4 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3524055A1 (de) * 2018-02-08 2019-08-14 BCSK Biocid GmbH Antibakterielles und spermizides gleitmittel
US20230407365A1 (en) * 2022-06-21 2023-12-21 Pamela Miles Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies
CN116059177A (zh) * 2022-12-14 2023-05-05 迪沙药业集团有限公司 一种克林霉素磷酸酯组合物及其制备方法
CN117535208B (zh) * 2024-01-04 2024-03-29 四川厌氧生物科技有限责任公司 一种卷曲乳杆菌及其在女性生殖道健康中的应用
JP7813333B1 (ja) * 2024-11-08 2026-02-12 日本食品化工株式会社 膣常在菌叢バランス改善剤及び膣用組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353146B1 (en) * 1998-04-20 2002-03-05 Playtex Products, Inc. Fibrous articles having odor adsorbtion ability and method of making same
ES2165139T3 (es) * 1998-04-30 2002-03-01 Vesely Renata Maria Cavaliere Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales.
EP1316530B1 (de) * 1999-04-26 2004-12-15 Tihomir Lelas Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel
KR20060128125A (ko) * 2005-06-09 2006-12-14 인하대학교 산학협력단 만델산을 유효성분으로 함유하는 질염 치료제
WO2007054085A2 (de) * 2005-11-11 2007-05-18 Ljubicic, Mijo Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum
SI2040837T1 (sl) 2006-07-04 2012-10-30 Gaston Glock Postopek za odločenje težkih kovin
CN101594888A (zh) * 2006-12-15 2009-12-02 欧兰益生公司 含有产乳酸细菌的吸收制品
WO2009133413A1 (en) * 2008-04-28 2009-11-05 Novatech D.O.O. Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism
EP2358642B2 (de) * 2008-11-21 2022-12-07 Froximun AG Klinoptilolith oder klinoptilolithhaltige gemische
KR101198572B1 (ko) * 2010-07-09 2012-11-06 경희대학교 산학협력단 미생물 감염증 치료 또는 개선용 조성물

Also Published As

Publication number Publication date
EP3167891A1 (de) 2017-05-17
CN106974932A (zh) 2017-07-25
EP3167890A1 (de) 2017-05-17
TR201904382T4 (tr) 2019-04-22
BR102016026252A2 (pt) 2017-05-23
JP2017088603A (ja) 2017-05-25
CA2947570C (en) 2021-08-10
CN106974932B (zh) 2021-05-04
ES2719223T3 (es) 2019-07-09
US20170136060A1 (en) 2017-05-18
JP6792420B2 (ja) 2020-11-25
AU2016247097B2 (en) 2021-12-02
EP3167891B1 (de) 2019-01-23
KR20170055932A (ko) 2017-05-22
AU2016247097A1 (en) 2017-06-01
CA2947570A1 (en) 2017-05-12

Similar Documents

Publication Publication Date Title
KR102335607B1 (ko) 질염의 치료
Miko et al. The role of hydrogen-peroxide (H2O2) produced by vaginal microbiota in female reproductive health
Sobel Vulvovaginal candidosis
Rajendran et al. Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation
Szerencsés et al. Size-dependent activity of silver nanoparticles on the morphological switch and biofilm formation of opportunistic pathogenic yeasts
Oliveira et al. Lactobacillus is able to alter the virulence and the sensitivity profile of Candida albicans
Wang et al. Susceptibilities of Malassezia strains from pityriasis versicolor, Malassezia folliculitis and seborrheic dermatitis to antifungal drugs
KR20130021764A (ko) 장내 미생물 효소복합체 및 이의 제조방법
Malfa et al. Evaluation of antimicrobial, antiadhesive and co-aggregation activity of a multi-strain probiotic composition against different urogenital pathogens
Huang et al. Antimicrobial substances and mechanisms of Lactobacillus rhamnosus against Gardnerella vaginalis
de Castro et al. Kicking sleepers out of bed: Macrophages promote reactivation of dormant Cryptococcus neoformans by extracellular vesicle release and non-lytic exocytosis
Gupta et al. Discovery of substituted isoxazolecarbaldehydes as potent spermicides, acrosin inhibitors and mild anti-fungal agents
CN116850191A (zh) 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用
Eade et al. The Anti‐HIV Microbicide Candidate RC‐101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa
Hrytsenko et al. The study of the antimicrobial activity of a soft dosage form with the antiviral effect
CN118924780A (zh) 肌苷酸在制备对细菌具有抑制作用的产品中的应用
Hassan et al. Zinc Oxide nanoparticles and curcumin affect some virulence genes of Staphylococcus aureus and Candida albicans, the cause of sub-clinical mastitis in buffalo
CN102198130A (zh) 紫草素作为抗真菌药物增效剂的用途
Kano et al. The first reported case of canine subcutaneous Cryptococcus flavescens infection
CN101961328B (zh) 鱼腥草素钠作为抗真菌药物增效剂的用途
BR102016026252B1 (pt) Uso de clinoptilolita no tratamento de vaginite
Servin et al. Probiotic potentials of Lactic acid bacteria isolated from vaginal swabs on selected genital pathogens.
Shahriari et al. Evaluation of mixture magnesium oxide and zinc oxide nanoparticles against multi-drug-resistance mycobacterium tuberculosis by microplate Alamar blue assay
Quindós et al. Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents
Obuekwe et al. The presence of microorganisms in some common excipients used in tablet formulation

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241202

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241202

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241202